$ARTV News

Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases

Artiva Biotherapeutics Announces Data Presentations On Allogenic NK Cell Therapy June 3-6

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41

Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40

Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40

Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA

HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $35

Artiva Biotherapeutics Stock Slides Despite Positive Trial Data

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Biotherapeutics Suspends Share Offering Under Sales Agreement With Leerink Partners

Artiva Biotherapeutics Q1 EPS $(0.95) Misses $(0.89) Estimate

Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $18 Price Target

Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?

Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $18 Price Target